drugset / Trial / NCT01209156

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01209156

Phase 1 Completed 11 enrolled Institute for Neurodegenerative Disorders
NaSingle-groupOpen-labelDiagnostic

Summary

The underlying goal of this study is to assess PBR-111 positron emission tomography (PET) imaging as a tool to detect microglial activation in the brain of Alzheimer disease (AD) research participants and age- and gender-matched healthy volunteers.

Timeline

Start
2010-03
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F] PBR111 Diagnostic / imaging agent 185 mbq Intravenous

Indications